HuiGene Therapeutics Completes RMB 400 Million Series B Financing to Advance Innovative Gene Therapies Toward Curing Diseases

VCBeat has learned that Hui-Gene Therapeutics (Shanghai) Co., Ltd. (hereinafter referred to as “Hui-Gene”), a Chinese company specializing in proprietary gene-editing tools, recently completed a B-round financing of RMB 400 million.This round of financing was jointly invested by multiple globally renowned funds, with continued support from existing shareholders. The funds will be used to support the company's technological innovation, preclinical R&D and clinical registration of products, construction of a pilot-scale platform for drug translation, and strengthening of the production and clinical development teams.

Previously, Hui-Gene Therapeutics completed a RMB 30 million angel financing round in November 2018 and a Series A financing round of over RMB 100 million in December 2019. For company information and product pipeline details, please visit the official website of Hui-Gene Therapeutics.

Dr. Yao Xuan, Founder and CEO of Hui-GeneHe stated, “In the less than three years since Hui-Gene Therapeutics was established, leveraging our team’s robust innovation, R&D capabilities, and execution, as well as our deep understanding of the gene editing therapy industry, the company has built a comprehensive technology platform covering the entire product development chain, including gene editing, delivery vectors, disease animal models, and drug translation. Meanwhile, multiple pipelines have achieved highly positive preclinical research results and entered the clinical trial application phase. Here, on behalf of Hui-Gene, I would like to thank our long-standing shareholders who have accompanied the company’s growth, as well as the new investors in this round for their continued recognition of Hui-Gene’s value and their strong support for our work. The translation of gene editing technology in China has gradually entered the validation phase, with the industry on the cusp of explosive growth. We welcome talented individuals committed to the research and development of gene therapies to join us, working together to build a flagship enterprise for gene therapy in China, aiming to cure diseases and bring the benefits of gene therapy to millions of patients.”

Hui-Gene Therapeutics was registered and established in Shanghai in October 2018. It is an innovative biopharmaceutical company focused on the development of gene editing technologies and gene therapy drugs. The company possesses globally leading RNA gene editing technology and gene ther-

Preclinical research and development platform, with a pipeline covering neurodegenerative diseases, visual impairments, hearing impairments, and other conditions. The company has assembled top global talent in early-stage innovative drug development, clinical research, and business development, while simultaneously strengthening its teams in drug translational manufacturing and clinical medicine. It aims to make gene therapy accessible to millions of patients in the near future and to become a leading global biopharmaceutical company.